Femasys Inc. (NASDAQ:FEMY) Sees Large Increase in Short Interest

Femasys Inc. (NASDAQ:FEMY) was the target of a significant growth in short interest in November. As of November 30th, there was short interest totalling 579,900 shares, a growth of 18.6% from the November 15th total of 489,100 shares. Currently, 2.7% of the shares of the stock are short sold. Based on an average daily trading volume, of 175,600 shares, the days-to-cover ratio is currently 3.3 days.

Hedge Funds Weigh In On Femasys

Institutional investors have recently modified their holdings of the company. Aljian Capital Management LLC acquired a new stake in shares of Femasys in the third quarter worth $27,000. XTX Topco Ltd boosted its holdings in Femasys by 123.9% in the 3rd quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock valued at $36,000 after purchasing an additional 18,004 shares during the period. Geode Capital Management LLC raised its position in shares of Femasys by 9.2% during the third quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock valued at $229,000 after buying an additional 17,473 shares during the last quarter. Finally, CM Management LLC increased its position in shares of Femasys by 6.3% during the second quarter. CM Management LLC now owns 425,000 shares of the company’s stock valued at $484,000 after purchasing an additional 25,000 shares during the period. Institutional investors own 65.27% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on FEMY shares. HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of Femasys in a report on Tuesday, December 3rd. Chardan Capital reduced their price objective on Femasys from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th.

Femasys Trading Up 0.8 %

Femasys stock traded up $0.01 during midday trading on Monday, reaching $1.20. The stock had a trading volume of 91,425 shares, compared to its average volume of 320,639. Femasys has a twelve month low of $0.73 and a twelve month high of $2.40. The company has a debt-to-equity ratio of 0.86, a current ratio of 3.94 and a quick ratio of 3.26. The firm has a market cap of $27.48 million, a price-to-earnings ratio of -1.47 and a beta of -2.89. The firm’s fifty day simple moving average is $1.14 and its two-hundred day simple moving average is $1.11.

Femasys (NASDAQ:FEMY) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). The business had revenue of $0.55 million for the quarter, compared to analyst estimates of $0.40 million. Femasys had a negative return on equity of 141.49% and a negative net margin of 1,435.77%. Equities analysts anticipate that Femasys will post -0.84 EPS for the current fiscal year.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.